Katelyn Desorcy-Scherer

Katelyn Desorcy-Scherer

Auto-generated profile, based on publicly available information

Katelyn Desorcy-Scherer

University of Wisconsin-Madison, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KDKatelyn Desorcy-Scherer
Katelyn Desorcy-Scherer
IZIbrahim Zuniga-Chaves
Ibrahim Zuniga-Chaves
MRMaggie A. Reisner
Maggie A. Reisner
GSGarret Suen
Garret Suen
LHLaura L. Hernandez
Laura L. Hernandez
Selective Serotonin Reuptake Inhibitor (SSRI) therapy is common among perinatal populations for the treatment of mood disorders. Medications can affect diversity and composition of the gut microbiome, which plays a key role in modulating health. While previous studies have examined the effects of antidepressant exposure on the maternal gut microbiome, whether SSRI exposure affects the offspring gut microbiome is unknown. We investigated the effects of maternal fluoxetine exposure on the gut microbiome of maternal and offspring mice during pregnancy and lactation (embryonic day 10–lactation day 21; E10–L21). Stool samples collected on E17, L11, L15, and L21 were examined using 16S rRNA sequencing. Our results suggest that maternal fluoxetine exposure may result in decreased alpha diversity of the offspring gut microbiome in early life. Furthermore, we observed several genera-specific differences in the gut microbiome based on treatment, specifically of Turicibacter, Parasutterella, and Romboutsia. These findings support our understanding of gut health, as dysbiotic development of the gut microbiome has been associated with local and systemic health problems including gastrointestinal morbidities and interrupted growth patterns in infants. Future research should pursue study in human populations and those at high risk for gut microbial dysbiosis and intestinal injury.

1 December 2023 in Developmental Psychobiology
Verified
Journal Article
Open access
KDKatelyn Desorcy‐Scherer
Katelyn Desorcy‐Scherer
HFHannah Fricke
Hannah Fricke
LHLaura L. Hernandez
Laura L. Hernandez
Perinatal mood disorders are a tremendous burden to childbearing families and treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants is increasingly common. Exposure to SSRIs may affect serotonin signaling and ultimately, microbes that live in the gut. Health of the gut microbiome during pregnancy, lactation, and early infancy is critical, yet there is limited evidence to describe the relationship between SSRI exposure and gut microbiome status in this population. The purpose of this Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA)‐compliant scoping review is to assess evidence and describe key concepts regarding whether SSRI exposure affects the maternal and infant gut microbiome. Sources were collected from PubMed, Web of Science, and Scopus databases, and an additional gray literature search was performed. Our search criteria returned only three sources, two rodent models and one human subjects research study. Results suggest that fluoxetine (SSRI) exposure may affect maternal gut microbiome dynamics during pregnancy and lactation. There were no available sources to describe the relationship between perinatal SSRI exposure and the infant gut microbiome. There is a significant gap in the literature regarding whether SSRI antidepressants affect the maternal and infant gut microbiome. Future studies are required to better understand how SSRI antidepressant exposure affects perinatal health.

7 February 2026 in Biological Research For Nursing
Verified
Journal Article
Closed access
KDKatelyn Desorcy-Scherer
Katelyn Desorcy-Scherer
KMKerry McNamara
Kerry McNamara
RLRyan Luellwitz
Ryan Luellwitz
ESEliot Stanton
Eliot Stanton
IZIbrahim Zuniga-Chaves
Ibrahim Zuniga-Chaves
Maternal selective serotonin reuptake inhibitor (SSRI) use is common during pregnancy and lactation. Changes in serotonin signaling may affect diversity and composition of microbes in the gut. Although research suggests SSRI drives microbial change, the extent to which the infant gut microbiome is affected is unknown. The infant gut microbiome is critical in early life for support of developmental health including early training of the immune system and metabolic programming. A total of N = 20 (10 SSRI, 10 control) maternal/infant dyads were enrolled in a pilot study. Thirty-six infant stool samples were collected at 1–2 and 4–6 weeks of life and sequenced using 16S rRNA sequencing. Investigative models included SSRI exposure as the primary variable of interest with infant feeding pattern and mode of delivery included as covariates. Maternal antidepressant use was not associated with infant alpha (within-sample) diversity. The SSRI use may shape beta (between-sample) diversity, particularly at weeks 4–6 of life ( p = .072). Increases in the genera Gemella , Staphylococcus and Corynebacterium were observed with SSRI exposure. Additionally, results reveal a SSRI-associated decrease in Lactobacillus . While this pilot study is not intended to provide conclusive evidence, it is an important step in informing future research directions. Results suggest a modest influence of maternal SSRI exposure on the infant gut microbiome. Future studies should seek to use techniques like metagenomics, providing functional information to assess for local or systemic health impact and ultimately, clinical relevance.

28 August 2023 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
KDKatelyn Desorcy-Scherer
Katelyn Desorcy-Scherer
MLMonica F. Torrez Lamberti
Monica F. Torrez Lamberti
MWMichael Weaver
Michael Weaver
GLGraciela L. Lorca
Graciela L. Lorca
LPLeslie A. Parker
Leslie A. Parker
Objective Preterm very low birth weight (VLBW) infants are at risk for intestinal morbidities and dysbiotic development of the intestinal microbiome. Despite the influence of sociodemographic factors on premature infant health outcomes, whether they shape the intestinal microbiome early in life is not clear. The objective was to explore the associations between race, sex, and socioeconomic status and the intestinal microbiome of VLBW infants during the first 4 weeks of life. Study Design This was a secondary analysis of data from an ongoing randomized trial of 79 infants ≤30 weeks' gestation and ≤1,500 g. Stool samples were collected at week 1 through week 4, frozen to −80°C and analyzed by 16S rRNA sequencing of the V4 region using Illumina MiSeq. Reads were analyzed to measure α and β diversity as well as relative abundance of bacteria in the intestinal microbiome. Results Of the 79 infants, 63 had at least one sample available. Twenty-three (37%) of infants were African American, 30 (48%) were male, and 44 (71%) had Medicaid insurance. There were no statistically significant (<0.05) differences in α diversity or β diversity, and the differential abundance analysis suggests limited patterns of distinction in the intestinal microbiome between non-African American and African American infants, male and female infants, and infants with maternal private or Medicaid insurance. Conclusion Our results suggest race, sex, and socioeconomic status shape colonization of specific microorganisms to a limited extent. Future studies should confirm these findings and determine clinical relevance through further study of differentially abundant microorganisms and additional factors contributing to colonization patterns. Key Points

3 December 2025 in Journal of Human Lactation
Verified
Journal Article
Closed access
KDKatelyn Desorcy-Scherer
Katelyn Desorcy-Scherer
KMKerry McNamara
Kerry McNamara
Background: Human milk contains messenger ribonucleic acid (mRNA), a key player in protein production and a source of gene expression information for understanding lactation physiology. The mRNA is renowned for its fragility and exists in several milk fractions, creating practical challenges for mRNA isolation and analysis. While research teams have developed protocols for the use of human milk samples in transcriptomic applications, it is unclear whether there are best practices in sample collection, storage, and processing procedures for the collection of the highest quality mRNA. Research Aim: We aim to review current practices in the collection, storage, and processing of human milk relevant for its use in transcriptomic applications (using mRNA) in the last 10 years. Method: The PubMed database was systematically searched for publications addressing methodological considerations or the use of mRNA derived from human milk samples. Results: Most sources described the collection of human milk from small cohorts of term mothers in a mature lactational stage. While fresh collection of human milk was common, some was frozen or preserved. Several centrifugation protocols exist, and considerations for collection, storage, and processing may vary by transcriptomic application. There is inconsistency in the description and reporting of mRNA quality used in analyses that obfuscates the determination of best practices for best mRNA quality. Conclusions: Research into the effects of human milk collection, processing, and storage on mRNA quality metrics is warranted.